GlobeNewsWire
09 Jun 2026, 10:38 UTC · 23w ago
Burning Rock Reports First Quarter 2026 Financial Results
Impact · against what's priced in
Burning Rock Biotech's Q1 2026 results are negative, characterized by a significant revenue decline and widening losses. While cost-cutting efforts are evident, the deterioration in high-margin pharma R&D services suggests fundamental headwinds to profitability.
- BNR−0.60
No priced-in read yet
- In context
Revenues fell 18.9% year-over-year to RMB107.9 million and net losses widened to RMB17.5 million, while gross margins in pharma R&D services dropped from 57.5% to 47.4%.
Read from the article alone





